*BRAVECTO® kills fleas and prevents flea infestations for 12 weeks. BRAVECTO® Chew and BRAVECTO® Topical Solution for Dogs kills ticks (black-legged tick, American dog tick, and brown dog tick) for 12 weeks and also kills lone star ticks for 8 weeks. BRAVECTO® Topical Solution for Cats kills black-legged ticks for 12 weeks and American dog ticks for 8 weeks. BRAVECTO® 1-MONTH Chews for Dogs and Puppies kill adult fleas, prevent flea infestations, and treat and control ticks (black-legged tick, American dog tick, and brown dog tick) for one month in dogs and puppies 8 weeks of age and older. BRAVECTO® 1-MONTH Chews also treat and control lone star ticks for one month in dogs and puppies 6 months of age and older.

 **A. Caninum

^†Prevents flea eggs from hatching.

References:

1. BRAVECTO® Chew for Dogs [prescribing information]. Madison, NJ: Merck Animal Health; 2014. 
2. BRAVECTO® Topical Solution for Dogs [prescribing information]. Madison, NJ: Merck Animal Health; 2016.
3. BRAVECTO® Topical Solution for Cats [prescribing information]. Madison, NJ: Merck Animal Health; 2016.
4. Freedom of Information Summary, NADA 141-459. Approved July 20, 2016.
5. SENTINEL® SPECTRUM® Chews [product label]. Madison, NJ: Intervet Inc.; 2020.
6. BRAVECTO® PLUS [product label]. Madison, NJ: Merck Animal Health; 2019.
7.  BRAVECTO® 1-MONTH (fluralaner) Chews [product label]. Millsboro, DE: Intervet, Inc; 2020.

IMPORTANT SAFETY INFORMATION
BRAVECTO 1-MONTH Chews: indicated for dogs 8 weeks of age and older.   The most commonly reported adverse reactions include itching, diarrhea, vomiting, decreased appetite, elevated ALT, lethargy, and weight loss. BRAVECTO 1-MONTH is not effective against A. americanum in puppies less than 6 months of age.  BRAVECTO Chews for Dogs: The most commonly reported adverse reactions include vomiting, decreased appetite, diarrhea, lethargy, polydipsia, and flatulence.  BRAVECTO Topical Solution for Dogs:  The most commonly reported adverse reactions include vomiting, hair loss, diarrhea, lethargy, decreased appetite, and moist dermatitis/rash.   BRAVECTO Topical Solution for Cats: The most commonly reported adverse reactions include vomiting, itching, diarrhea, hair loss, decreased appetite, lethargy, and scabs/ulcerated lesions. BRAVECTO Topical Solution for Cats is not effective against American dog ticks beyond 8 weeks of dosing. BRAVECTO PLUS Topical Solution for Cats:  The most commonly reported adverse reactions include vomiting, hair loss, itching, diarrhea, lethargy, dry skin, elevated ALT, and hypersalivation. BRAVECTO PLUS has not been shown to be effective for 2 months in kittens less than 6 months of age.  Use with caution in cats that are heartworm positive.  The effectiveness of BRAVECTO PLUS to prevent heartworm disease after bathing or water immersion has not been evaluated.

BRAVECTO has not been shown to be effective for 12-weeks' duration in puppies or kittens less than 6 months of age. BRAVECTO Chews and Topical Solution for dogs is not effective against the lone star tick beyond 8 weeks of dosing.  BRAVECTO Topical Solution for Dogs and Cats and BRAVECTO PLUS for cats are for topical use only.  Avoid oral ingestion.  The safety of BRAVECTO Topical Solution for Cats and BRAVECTO PLUS has not been established in breeding, pregnant and lactating cats.

All BRAVECTO products contain fluralaner, which is a member of the isoxazoline class.  This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures.  Seizures have been reported in dogs receiving isoxazoline class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders.  Neurologic adverse reactions have been reported in cats receiving isoxazoline class drugs, even in cats without a history of neurologic disorders. Use with caution in cats with a history of neurologic disorders. 

SENTINEL® SPECTRUM® Chews: Dogs should be tested for heartworm prior to use. Mild hypersensitivity reactions have been noted in some dogs carrying a high number of circulating microfilariae. Treatment with fewer than 6 monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention. For complete product information refer to the product insert.